1 Title page

- 2 Title: Potential Biases in Test-Negative Design Studies of COVID-19 Vaccine Effectiveness
- 3 Arising from the Inclusion of Asymptomatic Individuals
- 4 Authors: Edgar Ortiz-Brizuela^{1,2}, Mabel Carabali¹, Cong Jiang³, Joanna Merckx¹, Denis Talbot⁴,
- 5 *Mireille E. Schnitzer ^{3,5,1}
- 6 Affiliations:
- 7 1. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University,
- 8 Montreal, Quebec, Canada.
- 9 2. Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador
- 10 Zubirán, Mexico City, Mexico.
- 11 3. Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada.
- 12 4. Department of Social and Preventive Medicine, Université Laval, Quebec, Quebec, Canada.
- 13 5. Department of Social and Preventive Medicine, School of Public Health, Université de
- 14 Montréal, Montréal, Quebec, Canada.
- 15 Corresponding author: Mireille E. Schnitzer
- 16 **Contact information**:
- 17 Address: Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada.
- 18 Tel: 514 343-6111, extension: 0302
- 19 Email: <u>mireille.schnitzer@umontreal.ca</u>
- 20 Word Count:
- 21 Abstract: 195; Text: 3934.
 - 1

1 Abstract

2 The test-negative design (TND) is a popular method for evaluating vaccine effectiveness (VE). A 3 "classical" TND study includes symptomatic individuals tested for the disease targeted by the 4 vaccine to estimate VE against symptomatic infection. However, recent applications of the TND 5 have attempted to estimate VE against infection by including all tested individuals, regardless of 6 their symptoms. In this article, we employ directed acyclic graphs and simulations to investigate 7 potential biases in TND studies of COVID-19 VE arising from the use of this "alternative" 8 approach, particularly when applied during periods of widespread testing. We show that the 9 inclusion of asymptomatic individuals can potentially lead to collider stratification bias, 10 uncontrolled confounding by health and healthcare-seeking behaviors (HSBs), and differential 11 outcome misclassification. While our focus is on the COVID-19 setting, the issues discussed may 12 also be relevant in the context of other infectious diseases. This may be particularly true in 13 scenarios where there is either a high baseline prevalence of infection, a strong correlation between 14 HSBs and vaccination, different testing practices for vaccinated and unvaccinated individuals, or 15 settings where both the vaccine under study attenuates symptoms of infection and diagnostic 16 accuracy is modified by the presence of symptoms.

17 Keywords

18 Test-negative design, COVID-19, vaccine, effectiveness, asymptomatic, SARS-CoV-2,
19 simulation study, collider bias, confounding, misclassification.

20 Introduction

21 The post-licensure evaluation of COVID-19 vaccine effectiveness (VE), defined as the effect of vaccination on the risk of an infection-related outcome, $\frac{1}{2}$ has provided crucial insights into 22 questions not addressed through randomized clinical trials. $\frac{2-4}{2}$ Among the study designs used to 23 24 estimate VE, the test-negative design (TND) has gained popularity, in part because of its rapid and seemingly straightforward implementation.^{2,5,6} In a "classical" TND study, symptomatic 25 26 individuals tested for the disease targeted by the vaccine are prospectively selected, for example, from surveillance centers or hospitals.⁵⁻⁸ Then, VE against symptomatic infection is estimated by 27 28 comparing the odds of vaccination between patients with positive and negative test results using logistic regression. $\frac{5.7.8}{10}$ However, recent literature $\frac{9-20}{10}$ has also applied the term TND to studies 29 30 aiming to estimate VE against infection by including all tested individuals, regardless of their 31 symptom status (hereafter referred to as "alternative" TND) — for a clearer distinction between 32 classical and alternative TND, see **Box 1**. Nonetheless, this approach may introduce additional threats to validity and warrants a more comprehensive evaluation.²¹ 33

In this article, we investigate potential biases in TND studies of COVID-19 VE arising from the 34 35 use of this "alternative" approach, particularly when applied during periods of widespread testing. 36 We begin by discussing the identifiability of two causal target parameters: 1) the risk ratio (RR) 37 for medically attended and laboratory-confirmed symptomatic COVID-19 relative to vaccination status, referred to as RR_{COVID} (the target parameter for the classical TND), and 2) the RR for 38 SARS-CoV-2 infection relative to vaccination status, referred to as RR_{infect} (the target parameter 39 for the alternative TND) — note that throughout this manuscript we use the expression 40 41 "symptomatic COVID-19" to emphasize the difference between symptomatic and asymptomatic 3

42 infections. We conclude with a simulation study that aims to estimate and compare the magnitude 43 of the bias in the odds ratio (OR) estimates for medically attended and laboratory-confirmed 44 symptomatic COVID-19 (OR_{coVID}) and the OR for SARS-CoV-2 infection (OR_{infect}), relative to 45 their respective target parameters (RR_{coVID} and RR_{infect}), under scenarios where a classical TND 46 is considered valid.

47 Identifiability of target parameters

In this section, we use causal directed acyclic graphs (DAGs) to examine the identifiability of the target parameters (RR_{COVID} and RR_{infect}).²² By "identifiability," we refer to the ability to express a counterfactual quantity as a function of the distribution of observed data, implying the absence of systematic biases.^{23,24} However, before delving into the specifics of target parameter identifiability, and to facilitate a better understanding, we introduce the reader to a DAG based on previous work^{7,8,21,25,26} that illustrates the assumed causal relationships between relevant variables in TND studies of COVID-19 VE, whether classical or alternative (**Box 2**).

55 The case of the classical TND

In this context, if the test-negative state (having some illness that presents with COVID-19-like symptoms – such as an infection not targeted by the vaccine (I = 1) – and testing) and the vaccination status are independent conditional on covariates, the case-status OR (OR_{COVID}) relative to vaccination status — derived from a correctly specified multivariable logistic regression model — provides an unbiased estimate of its target parameter: the conditional RR for medically attended and laboratory-confirmed symptomatic COVID-19 (I = 2, S = 1, T = 1) relative to vaccination status (RR_{COVID}).^{8,27} Mathematical definitions for OR_{COVID} and RR_{COVID} are provided in **Box 3**. In

hospital-based TND studies, RR_{COVID} represents the risk ratio for medically attended infections leading to hospitalization (where *T* stands for "hospitalized and tested due to symptoms").⁸ On the other hand, in outpatient-based TND studies, RR_{COVID} represents the risk ratio for medically attended infections in outpatient settings (where *T* stands for "accessed care and tested").

Importantly, unlike some traditional case-control studies, the TND does not require the rare disease assumption for the OR to approximate the RR.⁸ It is also noteworthy that the OR_{COVID} estimate is often re-expressed as VE using the estimator: $\widehat{VE} = (1 - \widehat{RR}) \times 100.^{5}$ However, to avoid ambiguity, throughout this manuscript and unless otherwise specified, the term VE will continue to refer to any causal effect of vaccination on the risk of an infection-related outcome, regardless of the outcome assessed.¹

73 In addition, the estimands mentioned above can be given a causal interpretation if the identifiability assumptions are also met (Appendix S2).^{8,28,29} One such assumption, known as conditional 74 75 exchangeability, implies that all common causes of vaccination status (V) and outcome (medically attended and laboratory-confirmed symptomatic SARS-CoV-2 infection [I = 2, S = 1, T = 1]) 76 have been measured and appropriately accounted for in the analysis. $\frac{8,28-30}{10}$ However, among these 77 78 common causes, an individual's health and healthcare-seeking behaviors (HSBs) are inherently unmeasured.²¹ In a best-case scenario, if HSBs were deterministic (meaning that individuals who 79 80 exhibit these behaviors would always seek medical care when ill, while individuals who do not 81 exhibit HSBs would not), a classical TND study could mitigate bias related to this variable by 82 restricting the study population to individuals who have sought medical attention and are therefore assumed to exhibit HSBs (H = 1).^{5.7} Although this scenario seems unlikely in real-world settings, 83 84 where these behaviors may only modify the probability of seeking medical care, classical TND 5

studies could still offer better control for confounding by HSBs than other observational study
designs such as cohorts or traditional case-control studies.^{7.8}

87 To illustrate this point, Figure 1(a) shows a DAG that represents an ideal scenario for a classical 88 TND study evaluating VE against medically attended and laboratory-confirmed symptomatic 89 COVID-19. By "ideal", we mean that the study is conducted in a population where HSBs are 90 deterministic and only perfect tests are used (with 100% sensitivity and specificity). In this study, 91 the effect of interest is represented by the path $V \rightarrow I \bullet S \bullet T$. The square shapes of the nodes S, T, 92 and H indicate that the study sample is restricted to symptomatic and tested individuals who sought 93 medical care and therefore exhibit HSBs (S = 1, T = 1, H = 1). Conditioning on HSBs is critical because it not only allows control of confounding through the path $V \leftarrow H \rightarrow I$ but also blocks 94 95 other biasing paths (e.g., $V \leftarrow H \rightarrow T \leftarrow S \leftarrow I$) that were opened by conditioning on colliders such 96 as testing (T). In other words, restricting the study sample in a classical TND study to symptomatic 97 and tested individuals is essential to prevent (or minimize) confounding and collider-stratification bias by HSBs,⁷ and thus, to identify the RR_{COVID} . 98

99 The case of the alternative TND

100 Potential for collider stratification bias and uncontrolled confounding by HSBs

Having studied the classical TND, we now turn to the challenges presented by the alternative approach. In this scenario, since the study sample includes all tested individuals, regardless of symptoms, the target parameter is no longer the RR_{COVID} . Instead, it is the conditional RR for SARS-CoV-2 infection relative to vaccination status (RR_{infect}), represented by the path $V \rightarrow I$. Mathematical definitions for OR_{infect} and RR_{infect} are given in **Box 3**.

106 To assess the identifiability of this target parameter, it is crucial to identify the specific drivers of 107 testing leading to selection. Importantly, these drivers may have varied across settings, depending 108 on the stage of the pandemic and the prevailing indications for testing. $\frac{31,32}{5}$ For example, in a 109 prospective, nonprobability-based, cross-sectional online survey of testing practices conducted 110 between August 23, 2021, and March 12, 2022, among 418,279 U.S. adults aged ≥ 18 years, the 111 most common reasons for testing, other than having symptoms, were exposure to COVID-19 (23.1%), a prerequisite for travel (20.6%), and requirement for work or school (16.1%).³¹ Given 112 113 that some of these reasons were mandatory at various points in time, we can no longer assume that the study sample is limited to healthcare seekers, $\frac{21}{2}$ and that the TND effectively controls for bias 114 115 related to HSBs. This may also be relevant to some hospital-based TND studies, as some 116 institutions implemented policies for universal screening on admission.^{33,34}

We illustrate this point in the DAG shown in **Figure 1(b)**, which represents an alternative TND study of VE against SARS-CoV-2 infection. In this DAG, the circular shapes of the nodes HSBs (*H*) and COVID-19-like symptoms (*S*) indicate that we are no longer conditioning on these variables. As a result, several biasing paths are opened, leading to uncontrolled confounding by HSBs ($V \leftarrow H \rightarrow I$; path 1 in **Figure S1**) and collider stratification bias ($I \leftarrow H \rightarrow T \leftarrow S \leftarrow V$ (path 2); $V \rightarrow S \leftarrow I$ (path 3); $I \leftarrow H \rightarrow T \leftarrow V$ (path 4); $I \rightarrow S \rightarrow T \leftarrow V$ (path 5); and $V \leftarrow H \rightarrow$ $T \leftarrow S \leftarrow I$ (path 6)). In other words, the RR_{infect} is not identifiable in the alternative TND setting.

124 Potential for differential outcome misclassification

Another perceived benefit of the TND is its potential to reduce outcome misclassification compared to traditional cohort or case-control studies.^{7,8} This is primarily attributed to the restriction of the study sample to individuals with confirmed infection status.^{7,8} However, the 7

128 inclusion of asymptomatic individuals in alternative TND studies could potentially compromise 129 this apparent benefit and instead lead to differential misclassification of the outcome relative to 130 the exposure status. The main reason for this is that while SARS-CoV-2 diagnostic tests have 131 excellent specificity for diagnosing acute infection, their sensitivity is likely modified by the presence of symptoms.³² For example, two studies comparing the diagnostic accuracy of SARS-132 133 CoV-2 tests, reported antigen test sensitivities in symptomatic individuals of 72.0% (95% 134 confidence interval [95% CI], 63.7% to 79.0%) and 58.1% (95% CI, 40.2% to 74.1%) in those asymptomatic,³⁵ and nucleic acid amplification tests (NAATs) sensitivities in symptomatic 135 individuals of 97.1% (95% CI, 96.7% to 97.3%) and 87.6% (95% CI, 85.2% to 89.6%) in those 136 137 without symptoms. $\frac{36}{36}$

138 This concept is illustrated in the DAG shown in **Figure 1(c)**. This DAG introduces a new node for 139 the measured infection status (Ix), which may differ from its true value (I). There is differential 140 misclassification of the outcome (I) relative to the exposure status (V) because, as described in **Box 2**, COVID-19 vaccines (V) may affect the presence of symptoms (S), $\frac{37-39}{2}$ which in turn 141 modify the sensitivity of SARS-CoV-2 tests (represented by the path $V \rightarrow S \rightarrow Ix$). This situation 142 143 may be further complicated when considering that the selection of a specific test and its respective diagnostic performance, may depend on a number of additional factors.³² These include the 144 145 intended use of the test (i.e., screening versus confirmation, with molecular tests preferred for 146 confirming diagnoses of acute infection in symptomatic individuals $\frac{32,40}{2}$), the time of infection onset.⁴¹ the stage of the pandemic³², and the target population (e.g., travelers vs. frontline 147 workers $\frac{32}{2}$). As a result, it is difficult to accurately predict the magnitude and direction of this bias 148 149 without a comprehensive understanding of the causal structure underlying a given study. $\frac{42}{3}$

150 Simulation study

151 Methods

152 <u>Overview</u>

We conducted a simulation study to estimate and compare the magnitude of the bias in OR_{COVID} 153 and OR_{infect} estimates — relative to their respective target parameters (RR_{covid} and RR_{infect}) — 154 155 under scenarios where a classical TND is considered valid. For simplicity, all simulations assume causal consistency, $\frac{30}{10}$ no interference, $\frac{30}{10}$ positivity, $\frac{30}{10}$ and no unmeasured confounding other than 156 157 that related to HSBs. To assess the bias pathways, we divided the simulation study into two parts. 158 First, we evaluate the potential for collider bias and uncontrolled confounding by HSBs, assuming 159 perfect diagnostic tests. Second, we incorporate the potential for differential outcome 160 misclassification by simulating an extreme scenario where symptomatic individuals are tested 161 exclusively with NAATs, and asymptomatic individuals are tested exclusively with antigen tests. 162 Variables other than SARS-CoV-2 infection are assumed to be perfectly measured in all 163 simulations.

164 <u>Data generation process</u>

To generate realistic data consistent with the DAG shown in **Box 2**, we generated 1,000 datasets (each with 1,000,000 observations) that simulated a cumulative prevalence of SARS-CoV-2 infection of ~12.2%,⁴³ including an asymptomatic infection prevalence of ~35%,⁴⁴ and a cumulative prevalence of fully vaccinated individuals of ~54.6%.^{45,46} In addition, we simulated the proportion of individuals who reported using any SARS-CoV-2 diagnostic test (either NAATs or antigen tests) within 30 days in the aforementioned survey (~27.7%).³¹ Each node in the DAG

171 was generated conditionally on its parent nodes using the models shown in **Table 1**, with 172 parameters for these models selected based on the available literature whenever possible (**Table** 173 **S1**). Importantly, although the simulations were designed to represent an outpatient setting, similar 174 results can be expected for hospital-based TND studies, as the data generating structure may be 175 similar for both scenarios (**Box 2**).

176 Data analysis

177 After generating the data, we first created classical and alternative TND samples from each 178 simulated dataset by selecting either symptomatic and tested individuals or all tested individuals, 179 respectively. Second, we estimated the OR_{COVID} (in the classical samples) and the OR_{infect} (in the 180 alternative samples) using logistic regression models conditional on the set of measured 181 confounders (C). For these models, we used the true SARS-CoV-2 infection status as the outcome 182 variable when evaluating the potential for collider bias and uncontrolled confounding by HSBs, 183 and the measured SARS-CoV-2 infection status, when incorporating the potential for differential 184 outcome misclassification. Third, to estimate the true value of the target parameters (RR_{COVID} and RR_{infect}), we generated two counterfactual populations, each consisting of 100,000,000 185 186 individuals, representing scenarios in which everyone was either vaccinated or unvaccinated. 187 Finally, we estimated the bias by subtracting the true values of the target parameters from the 188 exponentiated mean of the log(OR) estimates obtained from the 1,000 simulated datasets (denoted as \widehat{OR}_{COVID} or \widehat{OR}_{infect}). Additionally, we report the Monte Carlo standard error (MCSE, the 189 190 standard deviation of the estimated log(ORs)) and the average standard error (aSE, the average of 191 the standard error estimates of the log(ORs)).

192 To investigate the potential for larger biases, we iterated over the processes described above, each 193 time varying the assumed strength of the relationships between the simulated variables. Specifically, we varied the magnitude of the association between H and V (parameter β_2 in **Table** 194 1), between H and both I = 1 and I = 2 (parameters $\gamma_{1,2}$ and $\gamma_{2,2}$, respectively), as well as the 195 196 relationships of I = 1 and I = 2 with S (δ_4 and δ_5 , respectively). We also varied the coefficient for the interaction term of I = 2 and V with S (δ_6), and the strengths of the relationships between 197 198 H and T (θ_2), between V and T (θ_3), and between S and T (θ_4). We adjusted these parameters 199 according to the direction of the association between the independent and dependent variables. 200 Specifically, for parameters representing a positive association (i.e., OR > 1), the strength was 201 increased by units of 1 from 1.5 to 10.5. Conversely, for parameters representing a negative 202 association (i.e., OR < 1), the strength was decreased from 0.95 to 0.05 by units of 0.1. We also 203 varied the intercepts for T (θ_0) and I = 2 ($\gamma_{2,0}$), aiming for a baseline prevalence of testing from 204 0.25 to 0.7 and for a baseline prevalence of acute SARS-CoV-2 infection from 0.05 to 0.5. Finally, 205 we simultaneously varied the strength of two, and then three, of the most influential parameters (i.e., β_2 , θ_3 , and the intercept for I = 2). It should be noted that any adjustment to these parameters 206 207 could lead to changes in the proposed prevalences for all simulated variables.

All analyses were performed using R (version 4.2.2, R Foundation for Statistical Computing,
Vienna, Austria, 2022).⁴⁷

210 Results

211 When we assessed the potential for collider bias and uncontrolled confounding by HSBs we found

a "true value" for RR_{COVID} of 0.149 and an estimated \widehat{OR}_{COVID} of 0.141 (MCSE and aSE = 0.019;

bias = -0.008). On the other hand, the "true value" for RR_{infect} was 0.142, with an estimated 11

 \widehat{OR}_{infect} of 0.125 (MCSE and aSE = 0.014; bias = -0.016). The results after varying the 214 215 strength of selected parameters for this scenario, either individually or simultaneously, are shown 216 in Figures 2-3 and Tables S2-S3. In every case, the classical TND outperformed the alternative in terms of bias, with the biases for \widehat{OR}_{COVID} and \widehat{OR}_{infect} ranging from -0.034 to -0.001 and 217 218 from -0.211 to 0.728, respectively. When we incorporated imperfect tests, we found estimates for \widehat{OR}_{COVID} of 0.154 (MCSE = 0.019; aSE = 0.018; bias = 0.005) and \widehat{OR}_{infect} of 0.146 219 220 (MCSE and aSE = 0.014; bias = 0.004), respectively. However, after varying the strength of 221 selected parameters for this scenario, either individually or simultaneously, we found larger bias for \widehat{OR}_{infect} (ranging from -0.188 to 0.766) than for \widehat{OR}_{COVID} (ranging from -0.005 to 0.018) 222 223 (Figures 4-5 and Tables S4-S5).

224 **Discussion**

The TND has become a preferred method for assessing VE against pathogens such as influenza, largely due to its seamless integration with existing laboratory-based surveillance systems.⁶ More recently, this observational study design has been widely used to estimate VE against COVID-19.²¹ This widespread application was made possible primarily by the extensive use of SARS-CoV-2 testing during the pandemic, which generated large amounts of potential data for TND studies.²¹ However, the use of these data for VE estimation poses unique validity challenges.²¹

Originally, the TND was proposed as an efficient way to identify a control group (test-negative controls) for individuals who contracted the vaccine-targeted infection (test-positive cases) while also accounting for confounding by HSBs.^{5,7,8} However, to effectively control for such bias in TND studies, researchers must assume that individuals seeking care and undergoing testing have

comparable HSBs.^{5,7,8} In the pre-COVID-19 era, testing for diseases such as influenza was 235 236 primarily driven by clinical indications and focused on those who actively sought care for 237 symptoms.⁴⁸ This arguably made it easier for researchers to assume that individuals enrolled in 238 TND studies had comparable HSBs, provided the same clinical definition was used for cases and 239 controls. However, this paradigm shifted with COVID-19, when testing criteria were expanded to 240 identify asymptomatic infections, often on a "mandatory" basis, in order to break transmission 241 chains.³² In this article, we have shown that TND applications that ignore this fact and include 242 individuals regardless of their symptoms (i.e., using the alternative TND) can potentially introduce 243 collider stratification bias, uncontrolled confounding by HSBs, and differential misclassification 244 of the outcome relative to the exposure status.

245 Our simulation study, based on educated guesses for parameter values and representing a scenario 246 in which the classical TND would yield unbiased estimates for its target parameter, showed only 247 minor bias in the alternative TND setting. However, we also showed that the inclusion of 248 asymptomatic individuals can lead to substantial bias in some scenarios. For example, our 249 simulations showed that as the effect of HSBs on vaccination increases (OR > 1), the estimated 250 \widehat{OR}_{infect} can become progressively closer to the null relative to its target parameter, RR_{infect} , 251 leading to further underestimation of VE when expressed as $1 - OR \times 100$. Similarly, in settings where vaccination status is more negatively correlated with testing (OR < 1), the \widehat{OR}_{infect} would 252 253 also be progressively biased towards the null. In addition, we observed that a higher baseline prevalence of SARS-CoV-2 infection would lead to a greater bias away from the null of \widehat{OR}_{infect} , 254 255 resulting in an overestimation of VE. We also found that these biases may be exacerbated by the 256 introduction of differential outcome misclassification when different diagnostic approaches are

used for symptomatic and asymptomatic individuals. Of note, the TND is well known to be particularly susceptible to misclassification bias compared to cohort and traditional case-control studies.⁴⁹ It is also important to mention that if one were to condition on the reason for testing or restrict the study sample to asymptomatic individuals, we would expect to observe the same bias described here, as all biasing pathways would remain open.

262 It could be argued that the biases discussed here may be only relevant to retrospective TND studies 263 that rely on routinely collected health data (i.e., data collected without predetermined research questions⁵⁰). For example, some TND studies using administrative data sources may have included 264 265 asymptomatic individuals simply because of a lack of information on reasons for testing, as 266 acknowledged by some authors. $\frac{14,15}{10}$ However, it should be noted that some retrospective TND 267 studies of COVID-19 VE intentionally included asymptomatic individuals to estimate VE against 268 infection, even when data on symptoms were available.^{10-12,16,17} In fact, some prospective TND 269 studies (i.e., those collecting primary research data) conducted during the COVID-19 pandemic also included individuals regardless of symptoms.¹⁸⁻²⁰ That said, the potential for inclusion of 270 271 asymptomatic individuals may be influenced not only by the data source, but also by the testing 272 practices in the specific context or time frame in which the study is conducted.

The changing landscape of COVID-19 testing practices throughout the pandemic further highlights the need for proper attention to context in TND studies. At the onset of the COVID-19 pandemic, testing was primarily NAAT-based and focused on symptomatic individuals.³² However, as the pandemic progressed, testing guidelines were modified to support mass testing of asymptomatic individuals as a tool for pandemic containment.³² Any TND study conducted under these circumstances, whether prospective or retrospective, would be at risk of the bias described here if a clinical definition was not included in the study's eligibility criteria. Thus, we believe that the issues discussed here are relevant not only to TND studies using routinely collected health and administrative data, but also to all studies conducted in settings where the rationale for testing extends beyond purely clinical reasons. **Box 4** provides a list of suggested strategies to minimize bias in TND studies conducted in such scenarios.

284 It is worth noting that there may be some specific circumstances in which the magnitude of the 285 biases discussed here could be attenuated by other features of the study design, particularly those 286 that allow for the selection of a population with comparable HSBs. For example, TND studies 287 focusing on booster effectiveness may be less susceptible to HSBs-related bias because subjects 288 in these studies typically have completed a primary immunization schedule and are therefore expected to have more similar HSBs.²¹ Likewise, some might argue that hospital-based TND 289 290 studies are likely to include individuals with more homogeneous HSBs because only those evaluated in clinical settings are eligible. However, as discussed elsewhere,⁷ it may be unrealistic 291 292 to assume that all hospitalized individuals have the same levels of HSBs. In addition, it should be 293 noted that not all SARS-CoV-2 tests performed in hospitals under pandemic conditions were 294 triggered by COVID-19-like symptoms; for example, some institutions mandated universal screening on admission.^{33,34} Consequently, hospital-based TND studies that include all individuals 295 tested regardless of the reason for testing, $\frac{13,51}{10}$ would be expected to have biases similar to those 296 297 discussed here.

298 This study has numerous strengths but also carries limitations. Among the strengths, our simulation

study was illustrated by DAGs, which helps to clarify the potential sources of bias. In addition,

300 while this article focuses on the COVID-19 setting, the issues discussed here are also relevant to

TND studies using the alternative approach in the context of other infectious diseases. This may be particularly true in scenarios of widespread testing, such as during epidemics or pandemics, where testing protocols and preferences are influenced by clinical and public health considerations, or in situations where self-testing for various infections is available.

305 In terms of limitations, the strength of the relationships depicted in the DAG may vary. For 306 example, the path between vaccination and testing $(V \rightarrow T)$ may be weak in some contexts. 307 Nevertheless, collider bias could still occur through these nodes because unobservable factors, 308 including HSBs, could confound the association between V and T. Another limitation lies in the 309 values assigned to the parameters in our simulations. Although we relied on existing literature, 310 these values are still estimates. However, varying these parameter values supported our theory-311 based hypothesis that relevant biases may occur in some settings. Finally, our study focused on 312 specific issues related to the inclusion of asymptomatic individuals in TND studies. However, we 313 did not assess additional complexities, such as the possibility of differential measurement error in 314 exposure, outcome, or covariate status based on testing rationale, or the nuances in data quality and challenges specific to their respective sources, such as clinical versus other settings. $\frac{21}{2}$ 315

316 Conclusions

In conclusion, the inclusion of asymptomatic individuals in TND studies of COVID-19 VE may lead to collider stratification bias, uncontrolled confounding by HSBs, and differential misclassification of the outcome relative to exposure status. Researchers designing or applying the TND for VE estimation need to be aware of these potential biases. Further research is needed to identify additional design or analytic strategies to control for biases related to HSBs that may improve the validity and utility of the TND for estimating VE against infection. 16

323 Data Availability Statement

324 Code and a sample simulated dataset are available and can be accessed here: 325 https://ortizbrizuela.github.io/projects/

326 Acknowledgements

- 327 Work supported by the Canadian Institutes of Health Research Project Grant ECP-184178
- 328 (awarded to MES, DT, JM, CJ). MES holds the Canada Research Chair in Causal Inference and
- 329 Machine Learning in Health Science. MC holds a Chercheur Boursier Junior 1 Award from the
- 330 Fonds de recherche du Québec-Santé (FRQS). DT holds a Chercheur Boursier Junior 2 Award
- from FRQS. E-OB holds a Doctoral Training Award from FRQS.

332 Conflicts of interest:

333 None.

334 **References**

- Cowling BJ, Sullivan SG. A concern over terminology in vaccine effectiveness studies.
 Euro Surveill 2018; 23(10).
- 337 2. Patel MM, Jackson ML, Ferdinands J. Postlicensure Evaluation of COVID-19 Vaccines.
 338 JAMA 2020; 324(19): 1939-40.
- 339 3. Prugger C, Spelsberg A, Keil U, Erviti J, Doshi P. Evaluating covid-19 vaccine efficacy 340 and safety in the post-authorisation phase. *BMJ* 2021; **375**: e067570.
- 341 4. Barouch DH. Covid-19 Vaccines Immunity, Variants, Boosters. N Engl J Med 2022;
 342 387(11): 1011-20.
- Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine
 effectiveness. *Vaccine* 2013; **31**(17): 2165-8.
- 6. Chua H, Feng S, Lewnard JA, et al. The Use of Test-negative Controls to Monitor Vaccine
 Effectiveness: A Systematic Review of Methodology. *Epidemiology* 2020; **31**(1): 43-64.
- 347 7. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative
- Study Design for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol* 2016; **184**(5):
 345-53.
- Schnitzer ME. Estimands and Estimation of COVID-19 Vaccine Effectiveness Under the
 Test-Negative Design: Connections to Causal Inference. *Epidemiology* 2022; **33**(3): 325-33.
- Song S, Madewell ZJ, Liu M, Longini IM, Yang Y. Effectiveness of SARS-CoV-2
 Vaccines against Omicron Infection and Severe Events: A Systematic Review and Meta-Analysis
 of Test-Negative Design Studies. *medRxiv* 2023: 2023.02.16.23286041.
- 355 10. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against
 356 SARS-CoV-2 Infection in Qatar. *N Engl J Med* 2021; **385**(24): e83.
- 11. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine
 effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med* 2021; 27(9): 1614-21.
- Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine
 effectiveness against the SARS-CoV-2 Delta variant in Qatar. *Nat Med* 2021; 27(12): 2136-43.
- Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against delta, mu, and
 other emerging variants of SARS-CoV-2: test negative case-control study. *BMJ* 2021; 375:
 e068848.
- 365 14. Skowronski DM, Setayeshgar S, Zou M, et al. Comparative Single-Dose mRNA and 366 ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2,
- Including Variants of Concern: Test-Negative Design, British Columbia, Canada. J Infect Dis 2022; **226**(1): 485-96.
- Ionescu IG, Skowronski DM, Sauvageau C, et al. BNT162b2 Effectiveness Against Delta
 and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged
 12-17 Years, by Dosing Interval and Duration. *J Infect Dis* 2023; 227(9): 1073-83.
- 372 16. Andrejko KL, Pry J, Myers JF, et al. Prevention of Coronavirus Disease 2019 (COVID-
- 373 19) by mRNA-Based Vaccines Within the General Population of California. *Clin Infect Dis* 2022;
- **74**(8): 1382-9.

Hitchings MDT, Ranzani OT, Torres MSS, et al. Effectiveness of CoronaVac among
healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus,
Brazil: A test-negative case-control study. *Lancet Reg Health Am* 2021; 1: 100025.

- 18. Li XN, Huang Y, Wang W, et al. Effectiveness of inactivated SARS-CoV-2 vaccines
 against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. *Emerg Microbes Infect* 2021; 10(1): 1751-9.
- 381 19. Singh C, Naik BN, Pandey S, et al. Effectiveness of COVID-19 vaccine in preventing
- 382 infection and disease severity: a case-control study from an Eastern State of India. *Epidemiol Infect*
- 383 2021; **149**: e224.
- Thiruvengadam R, Awasthi A, Medigeshi G, et al. Effectiveness of ChAdOx1 nCoV-19
 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a testnegative, case-control study and a mechanistic study of post-vaccination immune responses. *Lancet Infect Dis* 2022; 22(4): 473-82.
- Shi X, Li KQ, Mukherjee B. Current Challenges With the Use of Test-Negative Designs
 for Modeling COVID-19 Vaccination and Outcomes. *Am J Epidemiol* 2023; **192**(3): 328-33.
- Pearl J. Causal diagrams for empirical research. *Biometrika* 1995; 82(4): 669-88.
- 390 22. Pearl J. Causal diagrams for empirical research. *Biometrika* 1995; 82(4): 669-88.
 391 23. Hernán MA RJ. Chapter 2. Randomized experiments. Causal Inference: What If: Chapman
- 392 & Hall/CRC; 2020: 13-24.
- 393 24. Hernán MA RJ. Chapter 6. Graphical representation of causal effects. Causal Inference:
 394 What If: Chapman & Hall/CRC; 2020: 69-82.
- 395 25. Vandenbroucke JP, Pearce N. Test-Negative Designs: Differences and Commonalities
 396 with Other Case-Control Studies with "Other Patient" Controls. *Epidemiology* 2019; **30**(6): 838397 44.
- 26. Ciocanea-Teodorescu I, Nason M, Sjolander A, Gabriel EE. Adjustment for Disease
 Severity in the Test-Negative Study Design. *Am J Epidemiol* 2021; **190**(9): 1882-9.
- 400 27. Dean NE, Hogan JW, Schnitzer ME. Covid-19 Vaccine Effectiveness and the Test-401 Negative Design. *N Engl J Med* 2021; **385**(15): 1431-3.
- 402 28. Infante-Rivard C, Cusson A. Reflection on modern methods: selection bias-a review of 403 recent developments. *Int J Epidemiol* 2018; **47**(5): 1714-22.
- 404 29. Didelez V, Kreiner S, Keiding N. Graphical Models for Inference Under Outcome-405 Dependent Sampling. *Statistical Science* 2010; **25**(3): 368-87, 20.
- 406 30. Hernán MA RJ. Chapter 3. Observational studies. Causal Inference: What If: Chapman &
 407 Hall/CRC; 2020: 25-40.
- 408 31. Rader B, Gertz A, Iuliano AD, et al. Use of At-Home COVID-19 Tests United States,
- 409 August 23, 2021-March 12, 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(13): 489-94.
- 410 32. Peeling RW, Heymann DL, Teo YY, Garcia PJ. Diagnostics for COVID-19: moving from
 411 pandemic response to control. *Lancet* 2022; **399**(10326): 757-68.
- 412 33. Stadler RN, Maurer L, Aguilar-Bultet L, et al. Systematic screening on admission for
- 413 SARS-CoV-2 to detect asymptomatic infections. *Antimicrob Resist Infect Control* 2021; **10**(1): 44.
- 414 34. Talbot TR, Hayden MK, Yokoe DS, et al. Asymptomatic screening for severe acute 415 respiratory coronavirus virus 2 (SARS-CoV-2) as an infection prevention measure in healthcare
- 416 facilities: Challenges and considerations. *Infect Control Hosp Epidemiol* 2023; 44(1): 2-7.
- 417 35. Dinnes J, Deeks JJ, Adriano A, et al. Rapid, point-of-care antigen and molecular-based
- 418 tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev* 2020; **8**(8): CD013705.

419 36. Hohl CM, Hau JP, Vaillancourt S, et al. Sensitivity and Diagnostic Yield of the First SARS-

- 420 CoV-2 Nucleic Acid Amplification Test Performed for Patients Presenting to the Hospital. *JAMA*421 *Netw Open* 2022; 5(10): e2236288.
- 422 37. Antonelli M, Penfold RS, Canas LDS, et al. SARS-CoV-2 infection following booster 423 vaccination: illness and symptom profile in a prospective, observational community-based case-424 control study. *J Infect* 2023.
- 425 38. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-426 vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective,
- 427 community-based, nested, case-control study. *Lancet Infect Dis* 2022; **22**(1): 43-55.
- 428 39. Grana C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines. 429 *Cochrane Database Syst Rev* 2022; **12**(12): CD015477.
- 430 40. Government of Canada. (n.d.). Testing of vaccinated populations. Public Health Agency 431 of Canada. Retrieved May 10, 2023, from <u>https://www.canada.ca/en/public-</u> 422 health/agency/diagonalesting/testing/testing/testing/
- 432 <u>health/services/diseases/coronavirus-disease-covid-19/testing-screening-contact-tracing/testing-</u>
 433 <u>vaccinated-populations.html</u>.
- 434 41. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative
 435 Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time
 436 Since Exposure. *Ann Intern Med* 2020; **173**(4): 262-7.
- 437 42. Keogh RH, Shaw PA, Gustafson P, et al. STRATOS guidance document on measurement
 438 error and misclassification of variables in observational epidemiology: Part 1-Basic theory and
 439 simple methods of adjustment. *Stat Med* 2020; **39**(16): 2197-231.
- 440 43. World Health Organization. (n.d.). United States of America: WHO Coronavirus (COVID-
- 19) Dashboard. Retrieved from (April 10, 2023): <u>https://covid19.who.int/region/amro/country/us</u>.
- 44. Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: A
 443 systematic review and meta-analysis. *Proc Natl Acad Sci U S A* 2021; **118**(34).
- 444 45. U.S. Census Bureau. (n.d.). U.S. and World Population Clock. United States Census
 445 Bureau. Retrieved from (April 10, 2023): <u>https://www.census.gov/popclock/</u>.
- 446 46. Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations.
 447 Nat Hum Behav 2021; 5(7): 947-53.
- 448 47. R Core Team (2022). R: A language and environment for statistical computing. R
 449 Foundation for Statistical Computing, Vienna, Austria. URL <u>https://www.R-project.org/</u>.
- 450 48. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious
- 451 Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and
- 452 Institutional Outbreak Management of Seasonal Influenzaa. *Clin Infect Dis* 2019; **68**(6): e1-e47.
- 453 49. De Smedt T, Merrall E, Macina D, Perez-Vilar S, Andrews N, Bollaerts K. Bias due to 454 differential and non-differential disease- and exposure misclassification in studies of vaccine 455 effectiveness. *PLoS One* 2018; **13**(6): e0199180.
- 456 50. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using
- 457 Observational Routinely-collected health Data (RECORD) statement. *PLoS Med* 2015; **12**(10): e1001885.
- 459 51. Tan CY, Chiew CJ, Pang D, et al. Vaccine effectiveness against Delta, Omicron BA.1, and
- BA.2 in a highly vaccinated Asian setting: a test-negative design study. *Clin Microbiol Infect* 2023; **29**(1): 101-6.
- 462 52. Wu F, Yuan Y, Li Y, et al. The acceptance of SARS-CoV-2 rapid antigen self-testing: A 463 cross-sectional study in China. *J Med Virol* 2023; **95**(1): e28227.
 - 20

53. 464 Centers for Disease Control and Prevention. (2021, April 2). CDC updates travel guidance 465 for fully vaccinated people. Retrieved from April 13. 2023): (on 466 https://www.cdc.gov/media/releases/2021/p0402-travel-guidance-vaccinated-people.html.

467 54. Occupational Safety and Health Administration. (n.d.). Employer Rights and 468 Responsibilities Following a Federal OSHA Inspection. U.S. Department of Labor. Retrieved May

469 10, 2023, from <u>https://www.osha.gov/sites/default/files/publications/OSHA4159.pdf</u>.

470 55. World Health O. Evaluation of COVID-19 vaccine effectiveness: interim guidance, 17

471 March 2021. CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization, 2021.

Boxes

Box 1. *Relevant definitions used in this article.*

| "Alternative" Test- | An observational study design commonly used to estimate vaccine effectiveness (VE) against infection (whether |
|---------------------|---|
| Negative Design | symptomatic or asymptomatic). This design includes all individuals tested for the pathogen targeted by the |
| (TND) | vaccine under study, irrespective of their symptom status. VE is then estimated by comparing the odds of |
| | vaccination between individuals with positive and negative test results (test-positive cases and test-negative |
| | controls, respectively). |
| | |
| "Classical" TND | An observational study design commonly used to estimate VE against medically attended and laboratory- |
| | confirmed symptomatic infection. It includes individuals who are tested for the pathogen targeted by the vaccine |
| | under study due to the presence of symptoms. VE is then estimated by comparing the vaccination odds between |
| | individuals with positive and negative test results. Importantly, while both the alternative TND and the classical |
| | TND estimate VE, their specific objectives differ. While the alternative TND estimates VE against all infections, |
| | symptomatic or asymptomatic, the "classical" TND focuses only on VE against medically attended symptomatic |
| | infections. See below for definitions of infection and symptomatic infection. |
| | |
| Identifiability | The ability to express (identify) a counterfactual (causal) quantity, such as a measure of effect, as a function of |
| | the distribution of observed data, implying the absence of systematic bias. |
| | |
| Infection | The process by which a specific microorganism — the one targeted by the vaccine under study — invades and |
| | multiplies within an individual. An acute infection is usually confirmed by laboratory. Individuals with an |
| | infection may be asymptomatic, with no symptoms associated with the infection, or symptomatic, with |
| | symptoms associated with the infection. See the definition of "symptomatic infection" for more details. |
| | |

| Symptomatic | This term describes an individual with a laboratory-confirmed infection (e.g., via nucleic acid amplification test) |
|------------------|---|
| Infection | who also exhibit symptoms associated with that specific infection (e.g., fever, cough, or dyspnea in the case of |
| | COVID-19). |
| | |
| Target Parameter | The specific true measure of effect that a test-negative design study aims to estimate. |
| | |
| Vaccine | The effect of vaccination on the risk of an infection-related outcome. Specifically, it represents the expected |
| Effectiveness | reduction in the risk of an infection-related outcome that is directly attributable to vaccination. |
| | |

Box 2. Directed acyclic graph for test-negative design studies of COVID-19 vaccine effectiveness (either classical or alternative).



The path $I \rightarrow S \rightarrow T$ represents the typical sequence of events leading to a COVID-19 diagnosis for a patient presenting with COVID-19-like symptoms. For example, an individual may contract a SARS-CoV-2 infection (I = 2) or another type of infection (I = 1), develop symptoms (S = 1), and subsequently seek care, resulting in COVID-19 testing (T = 1). Because this is an observational study, the association between COVID-19 vaccination (V) and SARS-CoV-2 infection (I = 2) is expected to be confounded by both the presence of HSBs (H) and the set of measured confounders(C).² Specifically, for this demonstration, we assume that individuals who exhibit HSBs (H = 1) are more likely to be vaccinated (V = 1) and to engage in other healthy or preventive behaviors that may protect them against SARS-CoV-2 infection (I = 2). Furthermore, certain individual characteristics, such as advanced age or the presence of comorbidities (i.e., the set of measured confounders C), may increase the probability that individuals will be vaccinated (V = 1) and the probability that they will become infected with SARS-CoV-2 (I = 2).

We also assume that an individual's HSBs (*H*) are influenced by the set of measured confounders (*C*).⁷ In turn, these variables (*H* and *C*) influence an individual's probability of getting tested (represented by the path $H \rightarrow T \leftarrow C$). For example, older individuals, those with comorbidities, and those exhibiting HSBs (*H* = 1) may be more likely to get tested (*T* = 1) due to fear of potential complications.⁵² Additionally, we assume that vaccinated individuals (*V* = 1) may be less likely to get tested (*T* = 1) in some situations. For example, vaccinated individuals (*V* = 1) may attribute their symptoms (*S* = 1) to alternative causes (e.g., allergies or other infections (*I* = 1)), or they may be exempt from certain testing policies (e.g., for some travel-related or workplace screening programs[‡]).^{40,53,54} Moreover, we consider the possibility that vaccines may reduce symptoms or disease severity (e.g., hospitalization or death).³⁷⁻³⁹ Therefore, we allow COVID-19-like symptoms (*S*) to be directly affected by COVID-19 vaccination (*V*). Finally, we consider that the set of measured confounders (*C*) may influence the presence of COVID-19-like symptoms (*S*) (represented by the path $C \rightarrow S$).⁴⁴

Notes:

(*) For a brief introduction to the theory and terminology of DAGs, see Appendix S1.

(†) This DAG is applicable to both outpatient- and inpatient-based TND studies. In particular, the "testing" node can represent both hospitalization and testing in hospital-based TND studies (see Schnitzer, M. 2022 for an example).⁸

(‡) **Table S1** lists selected scenarios where testing practices varied between vaccinated and unvaccinated individuals during the pandemic.

$Classical TND^{*}$ $RR_{COVID} = \left(\frac{P(I = 2, S = 1, T = 1 | V = 1, H = 1, C)}{P(I = 2, S = 1, T = 1 | V = 0, H = 1, C)}\right)$ $OR_{COVID} = \left(\frac{P(I = 2 | V = 1, S = 1, T = 1, H = 1, C)}{P(I = 2 | V = 0, S = 1, T = 1, H = 1, C)}\right) / \left(\frac{P(I = 1 | V = 1, S = 1, T = 1, H = 1, C)}{P(I = 1 | V = 0, S = 1, T = 1, H = 1, C)}\right)$ $Alternative TND^{\ddagger}$ $RR_{infect} = \left(\frac{P(I = 2 | V = 1, C)}{P(I = 2 | V = 0, C)}\right)$

$$OR_{infect} = \left(\frac{P(I=2 \mid V=1, T=1, C)}{P(I=2 \mid V=0, T=1, C)}\right) / \left(\frac{P(I=1 \mid V=1, T=1, C)}{P(I=1 \mid V=0, T=1, C)}\right)$$

Notation:

- *C*: Confounders
- *H*: Health and healthcare-seeking behaviors
- I = 1: A test-negative COVID-19-like illness.
- I = 2: SARS-CoV-2 infection
- *S*: COVID-19-like symptoms
- *T*: SARS-CoV-2 diagnostic tests

• *V*: COVID-19 vaccination status

Notes:

(*) In the classical TND, the target parameter is the conditional risk ratio for medically attended and laboratory-confirmed symptomatic COVID-19. Therefore, the population of interest consists of individuals exhibiting HSBs (H = 1), with all SARS-CoV-2 infection (I = 2), symptoms (S = 1), and testing (T = 1) being part of the definition of RR_{COVID} . Furthermore, for OR_{COVID} to approximate RR_{COVID} , we require independence between the test-negative state (having some illness that presents with COVID-19-like symptoms – such as an infection non-targeted by the vaccine – and testing) and the vaccination status, conditional on covariates:

$$P(I = 1, S = 1, T = 1 | V = 1, H = 1, C) = P(I = 1, S = 1, T = 1 | V = 0, H = 1, C)$$

(‡) In the alternative TND setting, the target parameter is the conditional risk ratio for SARS-CoV-2 infection (I = 2), which includes both symptomatic and asymptomatic individuals. Since the study sample is not restricted to health care seekers, the target population is no longer limited to individuals with HSBs (H = 1). Our manuscript provides several reasons why this target parameter may not be identified under the alternative TND, i.e., why $OR_{infect} \neq RR_{infect}$.

480 Box 4. Suggested strategies for minimizing bias in TND studies conducted during infectious

- 481 *disease outbreaks.*
 - Researchers planning to assess vaccine effectiveness (VE) using the test-negative design (TND) should prioritize the validated classical form of this design and therefore must establish common eligibility criteria, including a clinical definition, for both test-positive cases and test-negative controls.
 - To effectively implement the validated classical form of TND, investigators should collect comprehensive symptoms data prior to testing, including their type and time of onset, as well as data on other reasons for testing. This detailed information may allow investigators to apply tailored eligibility criteria, thereby facilitating comparability of cases and controls in terms of health and healthcare-seeking behaviors (HSBs).
 - Because differences in the clinical presentation of vaccine-preventable infectious diseases may affect an individual's HSBs, researchers are advised not to pool data from inpatient and outpatient settings when using the TND.⁶ This step is important to maintain comparability between cases and controls with respect to HSBs.
 - When TND studies rely on routinely collected health and administrative data, investigators should attempt to obtain information on symptoms before testing (e.g., at admission for inpatient-based TND studies). If symptom information is not available, investigators may use alternative sources to define clinical eligibility criteria. For example, they may use hospital admission diagnoses as coded by the WHO International Classification of Diseases.
 - Investigators should select the most sensitive and specific tests available (e.g., NAATs for COVID-19) to minimize the potential for differential misclassification of outcomes in TND studies. In addition, researchers should consider the potential variation in diagnostic performance due to factors such as the timing of symptom onset. For example, to reduce misclassification errors, especially for infections where viral load peaks near the end of the incubation period, it may be advisable to prioritize testing near the time of symptom onset.⁵⁵
 - Given the many potential biases associated with the use of the TND to assess VE against infection, we recommend against using this design for this particular outcome.

Tables

Table 1: Models used in the simulation study to generate data consistent with the directed acyclic graph shown in Box 2.

| Variable (type) | Distribution / Parameters |
|--|---|
| C: Confounders (continuous) | Gaussian; $\mu = 40, \sigma = 4$ |
| H: Health and healthcare-seeking | Bernoulli; $expit(\alpha_0 + \alpha_1 C)$ |
| behaviors (binary: present vs. | where: |
| absent) | |
| | • $\alpha_0 = -19.4$, and $\alpha_1 = \log(1.59)$. |
| | • For a prevalence of $H \sim 0.37$. |
| | |
| V: COVID-19 vaccination (binary: | Bernoulli; $expit(\beta_0 + \beta_1 C + \beta_2 H)$ |
| vaccinated vs. unvaccinated) | where: |
| | β₀ = −12.25, β₁ = log(1.36), and β₂ = log(1.81). For a prevalence of V~0.55. |
| <i>I</i> = 1: Non-SARS CoV-2 infection | Bernoulli; expit($\gamma_{1,0} + \gamma_{1,1}C + \gamma_{1,2}H$) |
| (binary: present vs. absent) | where: |
| | γ_{1,0} = -6.7, γ_{1,1} = log(1.12), and γ_{1,2} = log(0.9). For a prevalence of I = 1~0.10. |
| <i>I</i> = 2: SARS-CoV-2 infection | Bernoulli; $expit(\gamma_{2,0} + \gamma_{2,1}C + \gamma_{2,2}H + \gamma_{2,3}V)^*(1 - I[I = 1])$ |
| (binary: present vs. absent) | where: |

| | γ_{2,0} = -5.4, γ_{2,1} = log(1.12), γ_{2,2} = log(0.9), and γ_{2,3} = log(0.1). For a prevalence of I = 2 ~0.12 and vaccine effectiveness of 90%. The term (1-I[I = 1]) was incorporated under the assumption that I = 1 and I = 2 are mutually exclusive. For simulations incorporating the potential for outcome misclassification, we generated the variable measured SARS-CoV-2 infection (Ix = 2) as shown in Figure 1(c), assuming a sensitivity of 0.97 for NAATs in symptomatic individuals and 0.58 for antigen tests in asymptomatic individuals, with a specificity of 0.99 for both tests. |
|--|--|
| <i>S</i> : COVID-19-like symptoms (binary: symptomatic vs. asymptomatic) | Bernoulli; expit(δ₀ + δ₁C + δ₂C: I[I = 1] + δ₃C: I[I = 2] + δ₄I[I = 1] + δ₅I[I = 2] + δ₆I[I = 2]:V) * (I[I = 1] + I[I = 2]) where: δ₀ = -33.8, δ₁ = log(1.2), δ₂ = log(1.93), δ₃ = log(1.93), δ₄ = log(10), δ₅ = log(10), and δ₆ = log(0.52). For a prevalence of S~0.65 among those with SARS-CoV-2 infection (I = 2). The term (I[I = 1]) + I[I = 2]) was included to ensure that symptoms only occur in individuals who have either I = 1 or I = 2. |
| <i>T</i> : COVID-19 diagnostic tests (binary: tested vs. not tested) | Bernoulli; $expit(\theta_0 + \theta_1 C + \theta_2 H + \theta_3 V + \theta_4 S) * (1 - I[H = 1, S = 1]) * (1 - I[H = 0, S = 1]) + I[H = 1, S = 1]$ where: • $\theta_0 = -38.8, \theta_1 = \log(2.47), \theta_2 = \log(1.3), \theta_3 = \log(0.92), \text{ and } \theta_4 = \log(6).$ • For a prevalence of $T \sim 0.28$. |

| • The terms $(1 - I[H = 1, S = 1]) * (1 - I[H = 0, S = 1]) + I[H = 1, S = 1]$ we | ere |
|--|-----|
| included to ensure that symptomatic individuals with HSBs would be tested whil | le |
| those without HSBs would not. | |
| | |
| | |

486 **Figures**

487 Figure 1: Causal-directed acyclic graphs for test-negative-design (TND) studies of COVID-19 vaccine effectiveness: a) the classical

488 TND setting, b) the alternative TND setting, c) potential for differential misclassification of outcome status in alternative TND studies.



489

490 Abbreviations: C: Confounders; H: health and healthcare-seeking behaviors; I: Infection status; Ix: Measured infection status; S:

- 491 COVID-19-like symptoms; *T*: SARS-CoV-2 diagnostic tests; *V*: COVID-19 vaccination status.
- 492 Notes: The square nodes indicate that the variable is controlled by either the study design or the analysis, while unconditioned nodes
- 493 are represented as circles.

- 494 *Figure 2*: Bias in odds ratio (OR) estimates for symptomatic COVID-19 (OR_{COVID}) and SARS-CoV-2 infection (OR_{infect}) relative to
- 495 their respective target parameters (RR_{COVID} and RR_{infect}) after varying the strength of selected parameters (assuming perfect SARS-
- 496 CoV-2 diagnostic tests).



Bias of the OR (exp(mean(measured log[OR])) - true RR)

- 498 Abbreviations: C: Confounders; H: health and healthcare-seeking behaviors; I: Infection status; I = 2: SARS-CoV-2 infection status;
- 499 OR, odds ratio; RR, risk ratio; S: COVID-19-like symptoms; T: SARS-CoV-2 diagnostic tests; TND, test-negative design; V: COVID-
- 500 19 vaccination status.

- 501 Figure 3: Bias in odds ratio (OR) estimates for symptomatic COVID-19 (OR_{COVID}) and SARS-
- 502 CoV-2 infection (OR_{infect}) relative to their respective target parameters (RR_{COVID} and RR_{infect})
- 503 after simultaneously varying the strength of two selected parameters (assuming perfect SARS-
- 504 *CoV-2 diagnostic tests*).



Bias of the OR (exp(mean(measured log[OR])) - true RR)





- 509 Figure 4: Bias in odds ratio (OR) estimates for symptomatic COVID-19 (OR_{COVID}) and SARS-CoV-2 infection (OR_{infect}) relative to
- 510 their respective target parameters (RR_{COVID} and RR_{infect}) after varying the strength of selected parameters (assuming symptomatic
- 511 individuals are tested exclusively with NAATs and asymptomatic individuals are tested exclusively with antigen tests).



36

- 513 Abbreviations: C: Confounders; H: health and healthcare-seeking behaviors; I: Infection status; I = 2: SARS-CoV-2 infection status;
- 514 NAATs, Nucleic Acid Amplification Tests; OR, odds ratio; RR, risk ratio; S: COVID-19-like symptoms; T: SARS-CoV-2 diagnostic
- 515 tests; TND, test-negative design; *V*: COVID-19 vaccination status.

- 516 Figure 5: Bias in odds ratio (OR) estimates for symptomatic COVID-19 (OR_{COVID}) and SARS-CoV-2
- 517 infection (OR_{infect}) relative to their respective target parameters (RR_{COVID}) and RR_{infect} after
- 518 simultaneously varying the strength of two selected parameters (assuming symptomatic individuals are
- 519 *tested exclusively with NAATs and asymptomatic individuals are tested exclusively with antigen tests).*



Bias of the OR (exp(mean(measured log[OR])) - true RR)



521 Abbreviations: *H*: health and healthcare-seeking behaviors; I = 2: SARS-CoV-2 infection status; 522 NAATs, Nucleic Acid Amplification Tests; OR, odds ratio; RR, risk ratio; *T*: SARS-CoV-2 diagnostic 523 tests; TND, test-negative design; *V*: COVID-19 vaccination status.

524